stockrowNewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.
- Revenue
- +5,406.9%
- EPS
- +77.1%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
Follow NAMS
Alert me
NewAmsterdam Pharma Company N.V. (NAMS) P/B ratio
As of 5 November 2026, NewAmsterdam Pharma Company N.V. (NAMS) trades at a P/B ratio of 3.7×. Over the past ten years it has ranged from 0.0× (December 2022) to 7.2× (May 2026); the current reading is higher than 54% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 6.1× | 89.88% |
| FY2024 | 3.2× | (5.97%) |
| FY2023 | 3.4× | 589.31% |
| FY2022 | 0.5× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 4.8× | (27.72%) |
| Jun 2026 | 6.6× | 13.06% |
| Mar 2026 | 5.9× | (3.65%) |
| Dec 2025 | 6.1× | 30.77% |
| 11 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| RXRX Recursion Pharmaceuticals, Inc. compare | 2.1× |
| CLDX Celldex Therapeutics, Inc. compare | 3.1× |
| NAMS NewAmsterdam Pharma Company N.V. | 3.7× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 4.5× |
| XNCR Xencor, Inc. compare | 5.2× |
| MBX MBX Biosciences, Inc. compare | 5.7× |
| PHVS Pharvaris N.V. compare | 6.4× |
| ADMA ADMA Biologics Inc compare | 6.7× |
| PVLA Palvella Therapeutics, Inc. compare | 10.4× |
| Biotechnology industry median | 2.0× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on NAMS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement